5,5-Difluoro-1,3,7,9-tetramethyl-2,8-bis(9,9,9',9'-tetrahexyl-9H,9'H-[2,2'-bifluoren]-7-yl)-10-(4-(9,9,9',9'-tetrahexyl-9H,9'H-[2,2'-bifluoren]-7-yl)phenyl)-5H-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (T-B2)
Using the general procedure A, the quantities used were: (T-B0Br) (90 mg, 0.16 mmol), (9,9,9',9'-tetrahexyl-9H,9'H-2,2'-bifluoren-7-yl)boronic acid (F 2 B) (513 mg, 0.722 mmol), Pd 2 (dba) 3 (20 mg, 0.022 mmol), P(t-Bu) 3 ·HBF 4 (36 mg, 0.12 mmol), K 3 PO 4 1.44 M (0.60 mL, 0.86 mmol). Column chromatography was performed using hexane:dichloromethane (7:3). The product was obtained as an intense pink powder (108 mg, 0.0466·mmol, 29%). 
13
C NMR (CDCl 3 , δ, 100 MHz): 154.56, 152.11, 151.75, 151.60, 151.21, 151.12, 142.70, 142.38, 140.91, 140.73, 140.53, 140.49, 140.46, 140.09, 139.94, 139.80, 139.15, 138.82, 134.78, 134.53, 132.32, 131.66, 128.98, 128.81, 127.90, 127.13, 126.92, 126.34, 126.27, 126.23, 126.15, 124.96, 123.06, 121.66, 121.55, 121.50, 120.25, 120.04, 120.02, 119.86, 119.72, 55.51, 55.35, 55.29, 40.49, 31.60, 31.57, 29.83, 29.73, 23.90, 22.70, 22.63, 14.15, 13.70, 13.42 5,5-Difluoro-2,8-bis(9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H-[2,2':7',2''-terfluoren]-7-yl)-10-(4-(9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H-[2,2':7',2''-terfluoren]-7-yl)phenyl)-1,3,7,9-tetramethyl-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (T-B3)
Using the general procedure A, the quantities used were: (T-B0Br) (100 mg, 0.178 mmol), (9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H,9'''H-2,2':7',2''-terfluoren-7-yl)boronic acid (F 3 B) (887 mg, 0.85 mmol), Pd 2 (dba) 3 (49 mg, 0.054 mmol), P(tBu) 3 ·HBF 4 (31 mg, 0.11 mmol), K 3 PO 4 1.44 M (0.88 mL, 1.3 mmol). Column chromatography was performed using hexane:dichloromethane (7:3). The product was obtained as an intense pink powder (295 mg, 0.0889 mmol, 50% 74, 152.41, 152.27, 152.19, 151.96, 151.63, 151.49, 142.71, 142.60, 141.25, 141.20, 141.02, 140.98, 140.90, 140.84, 140.58, 140.54, 140.47, 140.44, 140.31, 139.71, 139.28, 134.89, 134.62, 132.76, 131.96, 129.30, 129.24, 128.22, 127.46, 127.23, 126.52, 126.40, 125.42, 123.43, 121.96, 121.91, 121.68, 120.53, 120.38, 120.28, 120.09, 120.02, 55.91, 55.85, 55.74, 55.66, 40.77, 31.93, 30.09, 30.07, 30.03, 24.33, 24.29, 22.98, 22.92, 14.19, 13.76, 13.56 2,8-Bis(7-bromo-9,9-dihexyl-9H-fluoren-2-yl)-10-(4-(7-bromo-9,9-dihexyl-9H-fluoren-
0.26 mmol) and sodium acetate (66 mg, 0.8·mmol) were dissolved in dry tetrahydrofuran (16 mL). The solution was covered to exclude light and cooled to 0 ºC. A solution of bromine in dichloromethane (1.94 M, 1.3 mL, 2.5 mmol) was added to the previous solution. The reaction was stirred in the dark at 0 ºC for 30 min. The reaction was quenched with an aqueous saturated sodium sulphite solution and the mixture was dissolved in dichloromethane. The solvents were evaporated and the product was purified by column chromatography on silica gel eluting with hexane:dichloromethane (7:3). The product was dissolved in the minimum amount of dichloromethane and precipitated from methanol to yield a bright pink solid (224 mg, 0.144·mmol, 55%).
S9
140. 41, 140.17, 139.74, 139.69, 139.52, 134.69, 134.66, 133.24, 131.89, 130.43, 130.37, 129.39, 129.20, 128.21, 126.75, 126.70, 126.62, 125.34, 121.62, 121.47, 121.41, 120.58, 120.07, 56.08, 55.90, 40.68, 40.59, 31.89, 30.00, 29.93, 24.17, 22.95, 22.89, 22.86, 14.14, 13.70, 13.47 5,5-Difluoro-2,8-bis(9,9,9',9',9'',9'',9''',9'''-octahexyl-9H,9'H,9''H,9H'''-[2,2':7',2'':7'',2'''-quaterfluoren]-7-yl)-10-(4-(9,9,9',9',9'',9'',9''',9'''-octahexyl-9H,9'H,9''H,9'''H-
2,8-Bis(7-bromo-9,9-dihexyl-9H-fluoren-2-yl)-10-(4-(7-bromo-9,9-dihexyl-9H-fluoren- ,3,2] diazaborinin-4-ium-5-uide (T-B1Br) (100 mg, 0.0642 mmol), (9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H,9'''H -2,2':7',2''-terfluoren-7-yl)boronic acid (F 3 B) (311 mg, 152.30, 152.21, 151.97, 151.64, 151.50, 142.72, 142.60, 141.26, 140.99, 140.93, 140.84, 140.54, 140.49, 140.32, 139.72, 139.29, 134.89, 134.64, 132.77, 131.97, 129.24, 128.25, 127.48, 127.24, 126.54, 126.42, 125.43, 123.44, 121.97, 121.68, 120.54, 120.40, 120.30, 120.10, 55.92, 55.86, 55.75, 55.67, 40.79, 31.94, 30.09, 30.04, 24.35, 24.30, 22.99, 22.93, 14.21, 13 .78, 
yl)boronic acid (F n B (n = 1-4)) (1.6 equiv) and (Ata Phos) 2 PdCl 2 (0.1 equiv) were dissolved in dry tetrahydrofuran (20 mL). An aqueous solution of K 3 PO 4 (1.44 M, 1.5 equiv per boronic acid functionality) was added and the reaction mixture was degassed and heated up to 70 °C. It was refluxed under nitrogen for several hours.
The reaction mixture was quenched with water, diluted in dichloromethane and washed with brine and water. The combined organic fractions were dried over MgSO 4 and the solvent was evaporated. The crude product was purified by column S11 chromatography on silica gel eluting with hexane:dichloromethane (10:3). The product was dissolved in the minimum amount of dichloromethane and precipitated from methanol to yield a dark green powder.
3,7-Bis(9,9-dihexyl-9H-fluoren-2-yl)-10-(4-(9,9-dihexyl-9H-fluoren-2-yl)phenyl)-5,5-
Using the general procedure B, the quantities used were: (Y-B0Hal) (150 mg, 0.361 mmol), 9,9'-dihexylfluorenyl-2-boronic acid (F 43, 152.17, 151.97, 151.56, 151.03, 143.91, 143.29, 143.01, 141.72, 141.02, 140.96, 139.24, 137.07, 133.76, 131.82, 131.71, 130.92, 129.00, 127.99, 127.78, 127.37, 127.31, 127.25, 126.45, 124.55, 123.48, 123.44, 122.03, 121.49, 120.59, 120.56, 120.28, 119.78, 55.73, 55.68, 40.80, 40.61, 31.97, S12 31.90, 30.13, 30.08, 24.30, 24.18, 23.00, 22.94, 14.18 5,5-Difluoro-3,7-bis(9,9,9',9'-tetrahexyl-9H,9'H-[2,2'-bifluoren]-7-yl)-10-(4-(9,9,9',9'-
Using the general procedure B, the quantities used were: (Y-B0Hal) (100 mg, 0.240 mmol), (9,9,9',9'-tetrahexyl-2,2'-bifluoren-7-yl)boronic acid ( 41, 152.77, 152.49, 152.36, 151.98, 151.94, 151.50, 151.35, 143.91, 143.22, 142.73, 141.55, 141.43, 141.31, 141.23, 140.89, 140.86, 140.83, 140.23, 140.18, 139.25, 137.13, 133.80, 131.86, 131.73, 130.94, 129.15, 127.47, 127.39, 127.22, 126.58, 126.44, 124.62, 123.42, 122.08, 121.99, 121.96, 121.53, 120.89, 120.66, 120.58, 120.27, 120.10, S13 119.88, 55.92, 55.87, 55.67, 55.65, 40.83, 40.75, 40.63, 31.96, 31.93, 31.90, 30.08, 24.37, 24.26, 23.01, 22.96, 14.22, 14.18 5,5-Difluoro-3,7-bis(9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H-[2,2':7',2''-terfluoren]-7-yl)-10-(4-(9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H-[2,2':
Using the general procedure B, the quantities used were: (Y-B0Hal) (150 mg, 0.361·mmol), (9,9,9',9',9'',9''-hexahexyl-9H,9'H,9''H,9'''H-2,2':7',2''-terfluoren-7-yl)boronic acid ( 159. 44, 152.82, 152.53, 152.40, 152.30, 151.97, 151.50, 151.39, 143.94, 142.75, 141.56, 141.27, 141.01, 140.93, 140.84, 140.61, 140.47, 140.24, 139.28, 137.17, 131.89, 131.77, 127.47, 127.24, 126.58, 126.42, 124.68, 123.44, 122.02, 121.92, S14 120.93, 120.41, 120.30, 120.10, 119.92, 55.90, 55.86, 55.68, 40.79, 31.99, 31.96, 31.93, 30.11, 24.35, 24.30, 23.04, 23.00, 14.21 5,5-Difluoro-3,7-bis(9,9,9',9',9'',9'',9''',9'''-octahexyl-9H,9'H,9''H,9'''H-[2,2':7',2'':7'',2'''-quaterfluoren]-7-yl)-10-(4-(9,9,9',9',9'',9'',9'''-octahexyl-9H,9'H,9''H,9'''H-
Using the general procedure B, the quantities used were: (Y-B0Hal) (85 mg, 0.204·mmol), (9,9,9',9',9'',9'',9''',9'''-octahexyl-9H,9'H,9''H,9'''H,9''''H-2,2':7',2'':7'',2'''- 151. 39, 143.94, 142.75, 141.56, 141.26, 140.99, 140.93, 140.84, 140.61, 140.49, 140.28, 140.24, 139.28, 137.16, 131.89, 131.77, 127.47, 127.23, 126.53, 126.41, 124.66, 123.44, 121.97, 121.92, 121.56, 120.94, 120.62, 120.39, 120.29, 120.09, 55.89, 55.86, 55.66, 40.78, 31.98, 31.94, 30.10, 24.35, 24.29, 22.98, 14 The peaks of the most important absorption bands corresponding to the π -π*, S 0 -S 2 and S 0 -S 1 transitions are shown. Compound Calculated Absorption peaks, nm 
